Jump to content


Novartis Article in Latest Forbes Magazine

  • Please log in to reply
No replies to this topic

#1 LivingWellWithCML


    Advanced Member

  • Members
  • PipPipPip
  • 60 posts
  • LocationAtlanta, GA

Posted 27 May 2014 - 01:29 PM

Here is an article about Novartis betting big on T-cell treatment for blood cancers.  It has a lot of interesting details about the treatment, its progress, and the potential business model for Novartis.

There's also a mention about the increased "value" of Gleevec over the years, and the possibility of the US patent expiring as soon as next summer.  Very good read if you're into the details:


Dan - Atlanta, GA

CML CP Diagnosed March 2011

Gleevec 400mg

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users